Company Quick10K Filing
Ionis Pharmaceuticals
Closing Price ($) Shares Out (MM) Market Cap ($MM)
$0.00 142 $9,097
10-Q 2019-11-06 Quarter: 2019-09-30
10-Q 2019-08-08 Quarter: 2019-06-30
10-Q 2019-05-09 Quarter: 2019-03-31
10-K 2019-03-01 Annual: 2018-12-31
10-Q 2018-11-06 Quarter: 2018-09-30
10-Q 2018-08-07 Quarter: 2018-06-30
10-Q 2018-05-07 Quarter: 2018-03-31
10-K 2018-02-28 Annual: 2017-12-31
10-Q 2017-11-07 Quarter: 2017-09-30
10-Q 2017-08-09 Quarter: 2017-06-30
10-Q 2017-05-09 Quarter: 2017-03-31
10-K 2017-03-01 Annual: 2016-12-31
10-Q 2016-11-09 Quarter: 2016-09-30
10-Q 2016-08-09 Quarter: 2016-06-30
10-Q 2016-05-05 Quarter: 2016-03-31
10-K 2016-02-26 Annual: 2015-12-31
10-Q 2015-11-09 Quarter: 2015-09-30
10-Q 2015-08-05 Quarter: 2015-06-30
10-Q 2015-05-05 Quarter: 2015-03-31
10-K 2015-03-02 Annual: 2014-12-31
10-Q 2014-11-07 Quarter: 2014-09-30
10-Q 2014-08-04 Quarter: 2014-06-30
10-Q 2014-05-06 Quarter: 2014-03-31
10-K 2014-03-03 Annual: 2013-12-31
10-Q 2013-11-05 Quarter: 2013-09-30
10-Q 2013-08-06 Quarter: 2013-06-30
10-Q 2013-05-07 Quarter: 2013-03-31
10-K 2013-02-28 Annual: 2012-12-31
10-Q 2012-08-06 Quarter: 2012-06-30
10-Q 2012-05-09 Quarter: 2012-03-31
10-K 2012-02-29 Annual: 2011-12-31
10-Q 2011-11-08 Quarter: 2011-09-30
10-Q 2011-08-08 Quarter: 2011-06-30
10-Q 2011-05-06 Quarter: 2011-03-31
10-K 2011-03-01 Annual: 2010-12-31
10-Q 2010-11-05 Quarter: 2010-09-30
10-Q 2010-08-09 Quarter: 2010-06-30
10-Q 2010-05-07 Quarter: 2010-03-31
10-K 2010-03-01 Annual: 2009-12-31
8-K 2020-01-15 Enter Agreement, Officers, Exhibits
8-K 2020-01-09 Enter Agreement, Officers, Exhibits
8-K 2019-12-11 Off-BS Arrangement, Sale of Shares, Other Events, Exhibits
8-K 2019-12-11 Off-BS Arrangement, Sale of Shares, Other Events
8-K 2019-11-06 Earnings, Exhibits
8-K 2019-09-27 Leave Agreement
8-K 2019-08-07 Earnings, Exhibits
8-K 2019-06-10 Officers, Exhibits
8-K 2019-06-06 Shareholder Vote
8-K 2019-05-09 Earnings, Exhibits
8-K 2019-03-22 Officers, Exhibits
8-K 2019-02-27 Earnings, Exhibits
8-K 2018-12-21 Officers, Exhibits
8-K 2018-11-06 Earnings, Exhibits
8-K 2018-10-18 Officers, Exhibits
8-K 2018-10-10 Enter Agreement, Other Events, Exhibits
8-K 2018-09-25 Officers, Exhibits
8-K 2018-08-27 Other Events, Exhibits
8-K 2018-08-07 Earnings, Exhibits
8-K 2018-06-19 Officers, Exhibits
8-K 2018-05-30 Shareholder Vote
8-K 2018-05-04 Earnings, Other Events, Exhibits
8-K 2018-04-20 Sale of Shares, Exhibits
8-K 2018-03-15 Enter Agreement, Exhibits
8-K 2018-02-27 Earnings, Exhibits
8-K 2018-01-16 Officers

Ionis Pharmaceuticals Financials

IONS Metrics, Comps, Filings

Annual | Quarterly

Business

We are a leader in discovering and developing RNA-targeted therapeutics with sustained and growing revenues. We have created an efficient and broadly applicable drug discovery platform leveraging our expertise in antisense oligonucleotide therapeutics that we believe has fundamentally changed medicine and transformed the lives of people with devastating and often deadly diseases. Our large, diverse and advanced pipeline of over 40 first-in-class and/or best-in-class medicines addresses diseases across a broad range of therapeutic areas, targeting small, medium and large patient populations.

We have two commercial medicines approved in major markets around the world, SPINRAZA and TEGSEDI. We have at least four medicines that have entered pivotal studies or have the potential to begin pivotal studies this year, and another six medicines that could start pivotal studies in 2020. These medicines, along with the more than 30 additional medicines in our pipeline, represent multiple potential drivers of value for years to come. We believe our efficient drug discovery platform, coupled with our innovation-centric business model, provides us with the flexibility to determine the optimal development and commercialization strategy to maximize the commercial opportunity for each of our medicines and ensure that we continue to produce transformative medicines for patients who need them. We believe we are positioned to drive substantial value for patients and shareholders.

As of January 2019, SPINRAZA was approved in over 40 countries around the world, and our partner Biogen, who is responsible for global SPINRAZA commercial activities, reported that more than 6,600 patients are now on SPINRAZA therapy. In addition, Biogen plans to continue to pursue regulatory filings in additional countries. Biogen reported 2018 annual sales of SPINRAZA of more than $1.7 billion, and we earned $238 million in commercial revenues from royalties on sales of SPINRAZA. SPINRAZA is the first and only approved medicine for the treatment of spinal muscular atrophy, or SMA. SPINRAZA is the established standard-of-care for all people with this progressive, debilitating and often fatal genetic disease. In November 2018, SPINRAZA was recognized with the 2018 International Prix Galien award as Best Biotechnology Product. This prestigious honor marks the seventh Prix Galien award for SPINRAZA.


Valuation ($BB)

Market Cap, Enterprise Value

Balance Sheet ($BB)

Assets, Stockholders' Equity

Income Statement ($BB Annual)

Revenue, Gross Profit, Net Income

Cash Flow ($BB Annual)

Operating, Investing, Financing

Comps ($MM TTM) Market Cap Gross Margin EV/EBITDA Ret on Assets Assets Liabilities Revenue G Profit Net Income EBITDA EV
Elanco Animal Health (ELAN) 12,085 52% 30.6 2% 8,857 3,591 3,073 1,591 144 460 14,098
Mylan (MYL) 9,779 34% 8.3 0% 31,817 19,914 11,245 3,793 34 2,748 22,896
Teva (TEVA) 9,708 44% -13.7 -6% 59,424 44,173 17,720 7,741 -3,851 -2,437 33,498
Sarepta Therapeutics (SRPT) 9,465 0% -16.1 -33% 1,748 649 345 0 -570 -518 8,352
Ionis Pharmaceuticals (IONS) 9,097 57% 30.7 17% 2,878 1,421 799 459 495 287 8,825
Sage Therapeutics (SAGE) 8,814 51% -14.1 -47% 1,316 113 2 1 -613 -612 8,646
Bausch (BHC) 8,750 0% 25.1 -3% 32,354 29,666 8,425 0 -911 1,285 32,239
Alnylam Pharmaceuticals (ALNY) 7,978 91% -8.0 -32% 2,716 959 101 92 -858 -856 6,838
Catalent (CTLT) 7,731 32% 25.4 2% 6,184 3,896 2,518 805 137 408 10,377
Jazz Pharmaceuticals (JAZZ) 7,584 22% 10.2 12% 5,489 2,505 2,027 441 656 858 8,730
Dr Reddys Laboratories (RDY) 6,726 0% 225,427 85,230 0 0 0 0 6,714
Perrigo (PRGO) 6,361 38% 11.5 2% 11,429 5,702 4,652 1,747 218 761 8,788
Amarinuk (AMRN) 6,020 77% -69.5 -22% 390 241 307 236 -84 -84 5,865
Nektar Therapeutics (NKTR) 5,930 62% -14.8 -20% 2,100 542 119 73 -423 -394 5,844
Array Biopharma (ARRY) 5,260 92% -43.8 -22% 567 265 240 221 -126 -113 4,960
Galapagos (GLPG) 5,015 0% 1,439 225 0 0 0 0 5,015
Loxo Oncology (LOXO) 4,868 0% 697.4 1% 659 280 124 0 7 7 4,732
Blueprint Medicines (BPMC) 4,554 0% -11.7 -42% 807 214 8 0 -340 -333 3,886
Horizon Pharma (HZNP) 4,477 70% 16.5 2% 3,708 2,187 1,282 896 76 306 5,051
Taro Pharmaceutical Industries (TARO) 4,157 0% 2,135 224 0 0 0 0 3,589

Balance Sheet ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash706512416014312985130279
Accounts Receivable
Inventory9
PP&E36979186899093122132
Assets5504855468479569569121,3222,668
Accounts Payable7810111828212529
Long-Term Debt6146
Liabilities3063133634696987558139031,481
Stockholders' Equity2451711833782582011003311,048
Income Statement ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Revenue10899102147214284347508600
Cost of Revenue2
Gross Profit598
R&D145157158174239320340372412
SG&A12131315203749108245
Tax0000-1503-6-291
Net Income-61-85-65-61-39-88-87-17215
Cash Flow ($MM)2010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-31
Cash Operating-64-115263621-112174603
Cash Investing2411118-256-83-6057-358-930
Cash Financing5-139228602511229476